Author

D. C. Kahraman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:machine learning (classical)· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Koyas· 1 shared K. Narci· 1 shared N. Tuncbag· 1 shared R. Cetin Atalay· 1 shared R. Cetin-Atalay· 1 shared T. Ersahin· 1 shared T. Kahraman· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 11 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Koyas

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivMar 17, 2021

Context dependent isoform specific PI3K inhibition confers drugresistance in Hepatocellular carcinoma cells

K. Narci, D. C. Kahraman, A. Koyas…·R. Cetin Atalay

This study examines how isoform-specific PI3K inhibition affects drug resistance in hepatocellular carcinoma cells depending on PTEN status, showing synergistic and antagonistic effects with Sorafenib.

DOI 10.1186/s12885-022-09357-y

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivApr 25, 2018

Differential alteration of IL-8 in liver cancer stem cell enrichment in response to PI3K/Akt/mTOR inhibitors and sorafenib

D. C. Kahraman, T. Kahraman, R. Cetin-Atalay

The paper investigates how PI3K/Akt/mTOR inhibitors and Sorafenib affect liver cancer stem cell (LCSC) populations and identifies IL-8 as a key regulator of stemness.

DOI 10.1158/1535-7163.mct-19-0004

humanproteomics

𝕏 PostBluesky